Chugai Pharmaceutical Co Ltd (CHGCY)
15.22
+0.32
(+2.15%)
USD |
OTCM |
May 31, 16:00
Chugai Pharmaceutical Revenue (Quarterly): 1.597B for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.597B |
| December 31, 2023 | 1.854B |
| September 30, 2023 | 1.785B |
| June 30, 2023 | 1.949B |
| March 31, 2023 | 2.364B |
| December 31, 2022 | 3.110B |
| September 30, 2022 | 1.631B |
| June 30, 2022 | 1.818B |
| March 31, 2022 | 3.102B |
| December 31, 2021 | 2.835B |
| September 30, 2021 | 2.610B |
| June 30, 2021 | 2.023B |
| March 31, 2021 | 1.594B |
| December 31, 2020 | 2.015B |
| September 30, 2020 | 1.964B |
| June 30, 2020 | 1.754B |
| March 31, 2020 | 1.648B |
| December 31, 2019 | 1.631B |
| September 30, 2019 | 1.758B |
| June 30, 2019 | 1.510B |
| March 31, 2019 | 1.401B |
| December 31, 2018 | 1.360B |
| September 30, 2018 | 1.268B |
| June 30, 2018 | 1.262B |
| March 31, 2018 | 1.360B |
| Date | Value |
|---|---|
| December 31, 2017 | 1.298B |
| September 30, 2017 | 1.216B |
| June 30, 2017 | 1.146B |
| March 31, 2017 | 1.103B |
| December 31, 2016 | 1.194B |
| September 30, 2016 | 1.114B |
| June 30, 2016 | 1.182B |
| March 31, 2016 | 1.041B |
| December 31, 2015 | 1.079B |
| September 30, 2015 | 1.044B |
| June 30, 2015 | 1.015B |
| March 31, 2015 | 982.66M |
| December 31, 2014 | 1.116B |
| September 30, 2014 | 1.072B |
| June 30, 2014 | 959.11M |
| March 31, 2014 | 1.206B |
| December 31, 2013 | 1.166B |
| September 30, 2013 | 1.067B |
| June 30, 2013 | 1.120B |
| March 31, 2013 | 981.79M |
| December 31, 2012 | 1.367B |
| September 30, 2012 | 1.146B |
| June 30, 2012 | 1.187B |
| March 31, 2012 | 1.140B |
| December 31, 2011 | 1.260B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.510B
Minimum
Jun 2019
3.110B
Maximum
Dec 2022
2.028B
Average
1.836B
Median
Revenue (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 7.081B |
| Nxera Pharma Co Ltd | 31.07M |
| PeptiDream Inc | 28.47M |
| Healios KK | 0.0674M |
| AnGes Inc | 0.7651M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 501.30M |
| Total Expenses (Quarterly) | 923.59M |
| EPS Diluted (Quarterly) | 0.1523 |
| Enterprise Value | 45.03B |
| Gross Profit Margin (Quarterly) | 69.21% |
| Profit Margin (Quarterly) | 31.40% |
| Earnings Yield | 4.52% |
| Operating Earnings Yield | 6.10% |
| Normalized Earnings Yield | 4.516 |